DRI vs LGND: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

Reading it: DRI is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. DRI and LGND share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined DRI and LGND exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Darden Restaurants is the largest full-service restaurant company in the United States by revenue, operating more than 2,000 locations across a portfolio of brands. Its two volume engines are Olive Garden, the casual Italian chain that is its flagship, and LongHorn Steakhouse. Beyond those, Darden owns a cluster of fine-dining and specialty concepts including The Capital Grille, Eddie V's, Ruth's Chris Steak House (acquired in 2023), Yard House, Cheddar's Scratch Kitchen, Seasons 52, Bahama Breeze, and Chuy's, a Tex-Mex chain it acquired in late 2024 in a roughly ~$605 million all-cash deal as of that period.

Full DRI guide

Ligand Pharmaceuticals earns money three ways, and only one of them looks like a normal drug company. Royalties on partnered medicines were ~$48.0M of the ~$63.7M reported in the June 2026 quarter, split between rights carried as intangible royalty assets (Filspari at ~$13.6M, Kyprolis ~$7.0M, Ohtuvayre ~$4.1M, Rylaze ~$3.2M, plus Capvaxive, Vaxneuvance and teriparatide) and financial royalty assets accounted for more like loans (Qarziba ~$6.2M, an Ohtuvayre inventors stream ~$3.3M). Captisol, a modified cyclodextrin that makes poorly soluble injectable drugs formulable and sits inside products such as Amgen's Kyprolis and Baxter's Nexterone, added ~$8.0M of material sales. Contract revenue and milestone income supplied the remaining ~$7.7M. Ligand runs no salesforce and no manufacturing plant for the drugs it collects on, which is the whole point of the structure.

Full LGND guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• DRI drivers: Olive Garden and LongHorn carry the volume; Growth through acquisitions and new units.
• LGND drivers: The royalty line is compounding, not just holding; XOMA Royalty more than doubled the portfolio.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: Darden's results hinge on discretionary consumer spending, so a weaker economy or pressured household budgets can slow restaurant traffic and shrink average checks. For LGND, ligand controls none of the products it earns from, so a partner's pricing decision, launch stumble or patent loss lands straight in royalty revenue with no operational lever to pull.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick DRI if you believe its drivers more; LGND if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the DRI and LGND guides.

DRI. These figures are tied to the asOf date and round to fiscal 2026 results reported in June 2026; same-restaurant sales, margins, and valuation move with each quarter and with the stock price, so check a current quote and the latest filing before relying on any single number. Darden's fiscal year ends in late May, so its fiscal 2026 closed at the end of May 2026.

LGND. A sales multiple is close to meaningless for a royalty book, because royalty revenue carries essentially no cost of goods and the expense base is an office of dealmakers rather than a commercial organisation. Measured against guided 2026 adjusted earnings of ~$9.00 to ~$9.50, the stock sits near ~31x, and management points to operating cash flow above ~$200M this year and around ~$300M next. What that price embeds is an assumption that fresh royalty purchases keep arriving at accretive terms.

Headline figures (approximate, 2026-06-27): DRI shows revenue (fy2026) ~$13.21 billion, same-restaurant sales (fy2026) ~+4.5% blended, operating margin ~12%, dividend yield ~2.8-3.0%; LGND shows revenue (ttm) ~$291M, up ~55%, royalty revenue (q2 2026) ~$48.0M, up ~32% year over year, net income (ttm) ~$197M, about ~$9.19 per share, fy2026 guidance revenue ~$270M to ~$310M, adjusted EPS ~$9.00 to ~$9.50.

DRI and LGND are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined DRI and LGND exposure against your real portfolio. It is not an investment adviser.